Abstract
Branded biologic medicines generated an estimated $32bn of sales for the biotechnology and
pharmaceutical industries and represented the fastest growing group of medicines; while continued
high demand, high prices, and applicability in previously untreatable conditions are behind the
success of branded biologics, the absence of generic competition has meant that growth has gone
unchallenged. The Biogenerics Market Outlook: An analysis of market dynamics, growth drivers and
leading players, is a report which examines the key drivers and resistors behind the introduction of
generic biologic medicines in the European Union, United States and the rest of the world. This
report provides analysis on which companies will benefit from the advent of generic biologics and
identifies the companies who have the most to lose by examining the risks associated with the
leading biologic brands. By 2010, biologic medicines that accrue an estimated $11.2bn worth of sales
annually are expected to lose patent protection in developed pharmaceutical markets. This report
identifies strategies for biogenerics success and evaluates the obstacles that need to be overcome
in order to capture a share of this highly profitable, untapped market.
View Cart
